4,5,6,7-tetrahydro-1H-indole-2-carbaldehyde → 4-Piperidin-4-yl-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one
반응식
[NH:1]1[CH2:6][CH2:5][CH:4]([C:7]2[CH:15]=[CH:14][CH:13]=[C:12]3[C:8]=2[CH2:9][C:10](=[O:16])[NH:11]3)[CH2:3][CH2:2]1.[NH:17]1[C:25]2[CH2:24][CH2:23][CH2:22][CH2:21][C:20]=2[CH:19]=[C:18]1[CH:26]=O>>[NH:1]1[CH2:2][CH2:3][CH:4]([C:7]2[CH:15]=[CH:14][CH:13]=[C:12]3[C:8]=2[C:9](=[CH:26][C:18]2[NH:17][C:25]4[CH2:24][CH2:23][CH2:22][CH2:21][C:20]=4[CH:19]=2)[C:10](=[O:16])[NH:11]3)[CH2:5][CH2:6]1참가 물질
3
실험 절차
4-Piperidin-4-yl-1,3-dihydroindol-2-one (45 mg, 0.2 mmol) was condensed with 4,5,6,7-tetrahydro-1H-indole-2-carbaldehyde (33 mg, 0.23 mmol) to give the title compound.
출처 및 근거
- ORD 기록
- ord-479a4fedaca74cb0844f36bfbec08cb7
- 출처 데이터셋
- uspto-grants-2003_10
- 특허 번호
- US06635640B2
반응 노트
불러오는 중…